Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants-In vivo evidence

Journal of Carcinogenesis

Volumn 10, Issue , 2011, Pages

  Özten Kandas, Nur ^a   Bosland, Maarten ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Animal models; antioxidants; chemoprevention; clinical trials; natural compounds; prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; CATECHIN EPIGALLOCATECHIN 3 GALLATE; DUTASTERIDE; FINASTERIDE; GENISTEIN; GREEN TEA EXTRACT; LYCOPENE; POLYPHENOL DERIVATIVE; PRASTERONE; RESVERATROL; SELENIUM; SILIBININ; SILYBUM MARIANUM EXTRACT; TOREMIFENE; UNCLASSIFIED DRUG;

ARTICLE; CHEMOPROPHYLAXIS; DRUG BIOAVAILABILITY; HUMAN; IN VIVO STUDY; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; SILYBUM MARIANUM; SOYBEAN; TEA; THROMBOEMBOLISM; TUMOR GROWTH;

EID: 84867512375     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.90438     Document Type: Article

References (128)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases. In Vivo 1994;8:439-43.
3. Bosland MC, McCormick DL, Melamed J, Walden PD, Zeleniuch-Jacquotte A, Lumey LH. Chemoprevention strategies for prostate cancer. Eur J Cancer Prev 2002;11 Suppl 2:S18-27. (Pubitemid 35265859)
4. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, et al. Chemoprevention of prostate cancer: Concepts and strategies. Eur Urol 1999;35:342-50. (Pubitemid 29229531)
5. Steele VE, McCormick DL, Bosland MC, Rao KVN, Lubet RA. Identification of new agents for the prevention of prostate cancer using preclinical animal models. AACR Meeting Abstracts 2004;2004:938.
6. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001;98:10350-5. (Pubitemid 32803023)
7. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009;15:1947-53.
8. Harper CE, Patel BB, Wang J, Eltoum IA, Lamartiniere CA. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: Mechanisms of action. Prostate 2007;67:1576-89. (Pubitemid 47536156)
9. Bosland MC, Horton L, Weir R. Green tea extract does not protect against prostate cancer induction by MNU and testosterone in WU rats. AACR Meeting Abstracts 2005;2005:1428.
10. Condon MS, Agarwal S, van Weerden W, Bosland MC. Effects of green tea extract and caffeine on the growth of rat prostate cancer cells and the human prostate cancer xenograft PC346. Proc Am Assoc Res 2003;44:1100-1.
11. Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995; 214:833-8.
12. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 2009;275:86-92.
13. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. Faseb J 2011;25:1198-207.
14. Cho YM, Takahashi S, Asamoto M, Suzuki S, Tang M, Shirai T. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer Prostatic Dis 2007;10:378-83. (Pubitemid 350238088)
15. Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004;25:2217-24. (Pubitemid 39534860)
16. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46. (Pubitemid 351186384)
17. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40. (Pubitemid 43165995)
18. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008;54:472-3.
19. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007;67:11083-91. (Pubitemid 350145939)
20. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008;14:7773-80.
21. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008;68:6822-30.
22. National Toxicology Program. Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 2011:1-177.
23. Flaig TW, Glod M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70:848-55.
24. Harper CE, Cook LM, Patel BB, Wang J, Eltoum IA, Arabshahi A, et al. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 2009;69:1668-82.
25. Wang J, Eltoum IE, Carpenter M, Lamartiniere CA. Genistein mechanisms and timing of prostate cancer chemoprevention in lobund-wistar rats. Asian Pac J Cancer Prev 2009;10:143-50.
26. Wang J, Eltoum IE, Lamartiniere CA. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog 2007;6:3.
27. Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer Lett 2002;186:11-8. (Pubitemid 35245321)
28. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552S-8S. (Pubitemid 34208769)
29. McCormick DL, Johnson WD, Bosland MC, Lubet RA, Steele VE. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutr Cancer 2007; 57:184-93. (Pubitemid 47080091)
30. Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 2000;45:101-5.
31. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82. (Pubitemid 32896500)
32. Onozawa M, Kawamori T, Baba M, Fukuda K, Toda T, Sato H, et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res 1999;90:393-8. (Pubitemid 29213543)
33. El Touny LH, Banerjee PP. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype. Carcinogenesis 2007;28:1710-7. (Pubitemid 47289033)
34. El Touny LH, Banerjee PP. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009;69:3695-703.
35. Peterson G. Evaluation of the biochemical targets of genistein in tumor cells. J Nutr 1995;125(3 Suppl):784S-9S.
36. Linassier C, Pierre M, Le Pecq JB, Pierre J. Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity. Biochem Pharmacol 1990;39:187-93. (Pubitemid 20027986)
37. Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Current Opin Urol 2005;15:17-22. (Pubitemid 40105520)
38. Sarkar FH, Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 2002;21:265-80. (Pubitemid 36071914)
39. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-63. (Pubitemid 28513713)
40. Guo Q, Rimbach G, Moini H, Weber S, Packer L. ESR and cell culture studies on free radical-scavenging and antioxidant activities of isoflavonoids. Toxicology 2002;179:171-80. (Pubitemid 35245473)
41. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 1997;26:63-70. (Pubitemid 27060130)
42. Suzuki K, Koike H, Matsui H, Ono Y, Hasumi M, Nakazato H, et al. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 2002;99:846-52. (Pubitemid 34575703)
43. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr 2010;140:1355S-62S.
44. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-84. (Pubitemid 35435031)
45. Lund TD, Munson DJ, Haldy ME, Setchell KD, Lephart ED, Handa RJ. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 2004;70:1188-95. (Pubitemid 38387732)
46. Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-9. (Pubitemid 41724948)
47. Bovee TF, Schoonen WG, Hamers AR, Bento MJ, Peijnenburg AA. Screening of synthetic and plant-derived compounds for (anti)estrogenic and (anti)androgenic activities. Anal Bioanal Chem 2008;390:1111-9.
48. Maskarinec G, Morimoto Y, Hebshi S, Sharma S, Franke AA, Stanczyk FZ. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men. Eur J Clin Nutr 2006;60:1423-9. (Pubitemid 44857629)
49. Adams KF, Chen C, Newton KM, Potter JD, Lampe JW. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:644-8. (Pubitemid 38737902)
50. Kwan W, Duncan G, Van Patten C, Liu M, Lim J. A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr Cancer 2010;62:198-207.
51. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 2008;8:132.
52. DeVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer 2010. 62. 1036-43.
53. Grainger EM, Schwartz SJ, Wang S, Unlu NZ, Boileau TW, Ferketich AK, et al. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer 2008;60:145-54. (Pubitemid 351451270)
54. Schrder FH, Roobol MJ, Boev ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005;48:922-30; discussion 930-1. (Pubitemid 41641637)
55. Joniau S, Goeman L, Roskams T, Lerut E, Oyen R, Van Poppel H. Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. Urology 2007;69:1102-6. (Pubitemid 46891599)
56. Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK, et al. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology 2004;64:510-5. (Pubitemid 39200748)
57. Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol 2011;29:2386-90.
58. Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, et al. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer 2009;124:2050-9.
59. Hamilton-Reeves JM, Rebello SA, Thomas W, Kurzer MS, Slaton JW. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer 2008;60:7-13. (Pubitemid 351192916)
60. Hamilton-Reeves JM, Rebello SA, Thomas W, Slaton JW, Kurzer MS. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer. J Nutr 2007;137:1769-75. (Pubitemid 47037705)
61. Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol 2009;19:96-102.
62. Mucci LA, Spiegelman D. Vitamin D and prostate cancer risk-a less sunny outlook? J Natl Cancer Inst 2008;100:759-61. (Pubitemid 351809673)
63. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 2011;22:319-40.
64. Perez-Stable CM, Schwartz GG, Farinas A, Finegold M, Binderup L, Howard GA, et al. The G gamma/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiol Biomarkers Prev 2002;11:555-63. (Pubitemid 34615163)
65. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 2006;12:5895-901. (Pubitemid 44629623)
66. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807-18.
67. Barve A, Khor TO, Hao X, Keum YS, Yang CS, Reddy B, et al. Murine prostate cancer inhibition by dietary phytochemicals-curcumin and phenyethylisothiocyanate. Pharm Res 2008;25:2181-9.
68. Imaida K, Tamano S, Kato K, Ikeda Y, Asamoto M, Takahashi S, et al. Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis. Carcinogenesis 2001;22:467-72. (Pubitemid 32203827)
69. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007;28:1946-53. (Pubitemid 47500607)
70. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, et al. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008;9:7-14.
71. Adhami VM, Khan N, Mukhtar H. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer 2009;61:811-5.
72. Akaza H, Tsukamoto S, Morita T, Yamauchi A, Onozawa M, Shimazui T, Ideyama Y, Shirai T. Promoting effects of antiandrogenic agents on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl (DMAB). Prostate Cancer Prostatic Dis 2000;3:115-119. (Pubitemid 30663596)
73. Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998;82:531-7. (Pubitemid 28112992)
74. McCormick DL, Johnson WD, Lubet RA, Steele VE, Bosland MC. Differential chemopreventive activity of the antiandrogen, flutamide, and the antiestrogen, tamoxifen, in the rat prostate. Proc Am Assoc Cancer Res 2002;43:640.
75. Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr, et al. Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 2004;25:203-22. (Pubitemid 38328759)
76. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-7. (Pubitemid 39249705)
77. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
78. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
79. Gann PH. Prostate cancer. A closer look at the initial results from the REDUCE trial. Nat Rev Urol 2010;7:535-7.
80. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74. (Pubitemid 351767189)
81. Bosland MC, Cremers RG, Kiemeney LA. Words of wisdom. Re: effect of dutasteride on the risk of prostate cancer. Eur Urol 2010;58:631-2.
82. Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 1999;59:3084-9. (Pubitemid 29316006)
83. McCormick DL, Johnson WD, Kozub NM, Rao KV, Lubet RA, Steele VE, et al. Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5- androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis 2007;28:398-403. (Pubitemid 46321856)
84. McCormick DL, Rao KV, Steele VE, Lubet RA, Kelloff GJ, Bosland MC. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res 1999;59:521-4. (Pubitemid 29076042)
85. McCormick DL, Rao KV, Dooley L, Steele VE, Lubet RA, Kelloff GJ, et al. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all- trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res 1998;58:3282-8. (Pubitemid 28371066)
86. Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am JClin Oncol 1997;20:36-9. (Pubitemid 27066475)
87. Urban D, Myers R, Manne U, Weiss H, Mohler J, Perkins D, et al. Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol 1999;35:429-38. (Pubitemid 29229545)
88. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011;711:193-201.
89. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-36.
90. Klaunig JE, Wang Z, Pu X, Zhou S. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicology Appl Pharmacol 2011;254:86-99.
91. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grnberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
92. Lonkar P, Dedon PC. Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates. Int J Cancer 2011;128:1999-2009.
93. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995;62(6 Suppl):1427S-30S.
94. Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003;290:476-85. (Pubitemid 37430501)
95. Zhuo P, Diamond AM. Molecular mechanisms by which selenoproteins affect cancer risk and progression. Biochim Biophys Acta 2009;1790:1546-54.
96. Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta 2009;1790:1478-85.
97. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63. (Pubitemid 26427723)
98. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-4. (Pubitemid 28316638)
99. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95:1477-81. (Pubitemid 37279333)
100. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
101. Ozten N, Horton L, Lasano S, Bosland MC. Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model. Cancer Prev Res (Phila) 2010;3:371-80.
102. McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE. Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila) 2010;3:381-92.
103. Jiang Q, Christen S, Shigenaga MK, Ames BN. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001;74:714-22. (Pubitemid 33101790)
104. Barve A, Khor TO, Nair S, Reuhl K, Suh N, Reddy B, et al. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 2009;124:1693-9.
105. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato SY, et al. Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate 2009;69:644-51.
106. Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007;99:1074-85. (Pubitemid 47241392)
107. Bosland MC, Johnson WD, Cwik MJ, Lubet RA, Steele VE, McCormick DL. Lack of chemopreventive activity of lycopene in the Wistar-Unilever rat prostate cancer model. AACR Meeting Abstracts 2004;2004:900-c-.
108. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003;95:1578-86. (Pubitemid 37455925)
109. Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, et al. Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate 2010;70:1547-54.
110. Venkateswaran V, Klotz LH, Ramani M, Sugar LM, Jacob LE, Nam RK, et al. A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. Cancer Prev Res (Phila) 2009;2:473-83.
111. Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, et al. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 2002;227:886-93. (Pubitemid 35340343)
112. van Breemen RB. How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia? J Nutr 2005;135:2062S-4S. (Pubitemid 41099779)
113. van Breemen RB, Sharifi R, Viana M, Pajkovic N, Zhu D, Yuan L, et al. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prev Res (Phila) 2011;4:711-8.
114. Lee KW, Lee HJ. Biphasic effects of dietary antioxidants on oxidative stress-mediated carcinogenesis. Mech Ageing Dev 2006;127:424-31.
115. Calabrese V, Cornelius C, Trovato A, Cavallaro M, Mancuso C, Di Rienzo L, et al. The hormetic role of dietary antioxidants in free radical-related diseases. Curr Pharm Des 2010;16:877-83.
116. Chiang EC, Shen S, Kengeri SS, Xu H, Combs GF, Morris JS, et al. Defining the Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis. Dose-response 2009;8:285-300.
117. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005;65:2498-504. (Pubitemid 40490163)
118. Mao C, Qiu LX, Zhan P, Xue K, Ding H, Du FB, et al. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects. J Cancer Res Clin Oncol 2010;136:975-9.
119. Liwei L, Chunyu L, Ruifa H: Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology 2009, 74(4):884-888.
120. Kandas NO, Randolph C, Bosland MC. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutr Cancer 2009;61:251-64.
121. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12. (Pubitemid 36583728)
122. Navarro-Alarcon M, Cabrera-Vique C. Selenium in food and the human body: a review. Sci Total Environ 2008;400:115-41.
123. Abdulah R, Miyazaki K, Nakazawa M, Koyama H. Chemical forms of selenium for cancer prevention. J Trace Elem Med Biol 2005;19:141-50. (Pubitemid 41606711)
124. Zhang J, Wang L, Li G, Anderson LB, Xu Y, Witthuhn B, et al. Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr Cancer 2011;63:778-89.
125. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology 2001;57(4 Suppl 1):205-12. (Pubitemid 33733950)
126. Lieberman R. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. Urology 2001;57(4 Suppl 1):224-9. (Pubitemid 33733954)
127. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006;176:965-70; discussion 970-1
128. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549-56.